Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: Post-hoc analysis of a randomised placebo-controlled trial - Comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: Post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al
Pregnolato F.;Sciascia S.;
2022-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.